Determinants of the haemoglobin level in patients with sickle cell disease living in sub-Saharan Africa: Major impact of the country of residence and independent effects of leucocyte and platelet counts and haemolysis
- PMID: 38831605
- DOI: 10.1111/bjh.19576
Determinants of the haemoglobin level in patients with sickle cell disease living in sub-Saharan Africa: Major impact of the country of residence and independent effects of leucocyte and platelet counts and haemolysis
Abstract
The degree of anaemia in sickle cell disease (SCD) is a well-known contributor to morbidity and mortality. We aimed to explore the factors affecting haemoglobin (Hb) level in African SCD patients, considering haemolysis biomarkers (LDH and bilirubin level, and reticulocyte count), leucocyte and platelet counts and socio-demographic characteristics (gender, age group, country of residence and BMI). The research was part of the CADRE multinational cohort and involved 3699 SCD patients living in Mali, Senegal, Ivory Coast, Democratic Republic of Congo, Gabon and Cameroon: 2936 SS/Sβ0, 587 SC and 176 Sβ + patients with median Hb level of 8, 11.3 and 11.2 g/dL respectively (p < 0.001). In multivariate analysis conducted in 1394 SS/Sβ0 patients, living in Cameroon, female gender, lower BMI, higher haemolysis markers (especially LDH) and higher leucocyte and platelet counts were independently associated with lower Hb level (all p < 0.05). In 497 SC and 156 Sβ + patients, female gender (p < 0.001), lower BMI (p < 0.05) and higher platelet counts (p < 0.001) were independently associated with lower Hb level. Anaemia in African SCD patients is not only associated with haemolysis but also with the country of residence, lower BMI and leucocyte or platelet counts which might reflect inflammation related to infectious burden in the region.
Keywords: epidemiology; haemoglobin; haemolysis; sickle cell disease.
© 2024 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
References
REFERENCES
-
- Thomson AM, McHugh TA, Oron AP, Teply C, Lonberg N, Vilchis Tella V, et al. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the global burden of disease study 2021. Lancet Haematol. 2023;10(8):e585–e599.
-
- Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene‐Frempong K, Krishnamurti L, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4(1):18010.
-
- Quinn CT. Minireview: clinical severity in sickle cell disease: the challenges of definition and prognostication. Exp Biol Med. 2016;241(7):679–688.
-
- Rees DC, Brousse VAM, Brewin JN. Determinants of severity in sickle cell disease. Blood Rev. 2022;56:100983.
-
- Miller ST, Wang WC, Kinney TR. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000;7:83–89.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
